Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2005
11/09/2005EP1144371B1 Benzenesulphonamide derivatives and their use as mek inhibitors
11/09/2005EP1100788B1 Substituted quinazoline derivatives
11/09/2005EP1095016B1 Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
11/09/2005EP1089973B1 Amidino and guanidino azetidinone tryptase inhibitors
11/09/2005EP1075519B1 Inhibitors of nf-kb activation
11/09/2005EP1066266B1 Cyclin dependent kinase inhibitors
11/09/2005EP1066041B1 THE USE OF17-ALPHA-ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY
11/09/2005EP1049700B1 Chemokine receptor antagonists and methods of use therefor
11/09/2005EP1043982B1 Lipase inhibiting polymers
11/09/2005EP1019392B1 Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
11/09/2005EP1019389B1 Epothilone derivatives
11/09/2005EP1019089B1 Long-acting drugs and pharmaceutical compositions comprising them
11/09/2005EP0988285B1 Prodrug forms of ribonucleotide reductase inhibitors 3-ap and 3-amp
11/09/2005EP0975353B1 Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
11/09/2005EP0960192B1 Synthetic polynucleotides
11/09/2005EP0943008B1 Metal mediated serine protease inhibitors
11/09/2005EP0928290B9 Oligoribonucleotides and ribonucleases for cleaving rna
11/09/2005EP0842278B1 Dnase-active protein
11/09/2005EP0772455B1 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy
11/09/2005EP0751992B1 Vascular endothelial growth factor 2
11/09/2005CN1694879A Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
11/09/2005CN1694875A 5-aryltetrazole compounds and uses thereof
11/09/2005CN1694719A Casein derived peptides and uses thereof in therapy
11/09/2005CN1694707A Pde-v inhibitor and medicine composite with active agent
11/09/2005CN1694702A Neurotrophic factor production promoter
11/09/2005CN1694697A Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for
11/09/2005CN1694692A Hypogastric and/or perineal pain-relieving agent
11/08/2005US6963011 Central nervous system disorders; psychological disorders
11/08/2005US6963010 Hydrophobic polyamine analogs and methods for their use
11/08/2005US6962996 Inhibitors of p38
11/08/2005US6962993 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/08/2005US6962978 Multiple sclerosis; immobilization; water solubility
11/08/2005US6962969 Compounds and methods for modulating nonclassical cadherin-mediated functions
11/08/2005US6962942 Azacycloalkanone serine protease inhibitors
11/08/2005US6962941 such as 1,4-Bis-{N-[3-(3-aminomethylphenylproplonyl)-2-methoxycarbonylpyrrolidin-4-yl]aminocarbonyloxy}-2-butyne dihydrochloride; for treatment of asthma, allergic conjunctivitis, allergic rhinitis, psoriasis, and ulcerative colitis
11/08/2005US6962940 Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders
11/08/2005US6962939 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
11/08/2005US6962937 Imidazolidine derivatives, their preparation and their use
11/08/2005US6962936 Treating diseases such as cancer, inflammatory disorders, restenosis,
11/08/2005US6962933 cerebral hemorrhage/infarction, head trauma, spinal cord injury, brain edema, multiple sclerosis, Alzheimer's/Parkinson's disease, amyotrophic lateral sclerosis, diabetes, osteoporosis, Creutzfeldt-Jakob disease or virus infections
11/08/2005US6962931 Oral bioavailability of a CETP inhibitor
11/08/2005US6962924 Antihistamines; side effect reduction
11/08/2005US6962918 Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
11/08/2005US6962915 Antiinflammatory agents
11/08/2005US6962911 Treatment of impotence, sexual dysfunction in female, stable, unstable and variant angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis
11/08/2005US6962905 Pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
11/08/2005US6962900 Pharmaceutical being used for treating HIV infection, the composition and uses thereof
11/08/2005US6962799 Microtubule-associated proteins and tubulins
11/08/2005US6962792 cyclin-dependent kinase 4 (CDK4); useful in treatment of tumours and other hyperproliferative disorders
11/08/2005US6962720 Triterpene compositions and methods for use thereof
11/08/2005US6962705 Bacterial crystal protein and nucleotide sequences for generating transgenic insect resistant plants
11/08/2005CA2310950C An efficacious dosage regiment of galantamine that reduces side effects
11/08/2005CA2221255C Use of selegiline to treat hearing loss in mammals
11/08/2005CA2195677C Endothelin antagonists
11/08/2005CA2157288C Methods and compositions for inhibition of angiogenesis
11/08/2005CA2155104C Heterocyclic-substituted alkyl amide acat inhibitors
11/06/2005CA2504403A1 Prognostic for hematological malignancy
11/03/2005WO2005103288A1 Screening method
11/03/2005WO2005103012A1 Hydrazino-substituted heterocyclic nitrile compounds and use thereof
11/03/2005WO2005102981A1 Novel compounds and medicinal use thereof
11/03/2005WO2005102456A1 Composition and method for cancer treatment
11/03/2005WO2005102388A1 Novel blt2-mediated disease, and blt2 binding agent and compound
11/03/2005WO2005102381A1 Bone densifying agent characterized by use of cathepsin k inhibitor with pth
11/03/2005WO2005102369A1 Pharmaceutical preparation containing bacterial cell wall skeleton component
11/03/2005WO2005102344A1 Pharmaceutical composition
11/03/2005WO2005102321A1 Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis
11/03/2005WO2005002555A3 Sirt1 modulators for manipulating cell/organism lifespan/stress response
11/03/2005WO2003068168A3 Helical peptidomimetics and use b-amyloid-associated diseases
11/03/2005US20050245750 Process for preparing 1,3-benzodioxole-2-spirocycloalkane derivative
11/03/2005US20050245743 depression and/or anxiety, obesity, urinary disorder; 5-(2-Methoxyphenyl)-N-[3-(4-Piperidinyl)Phenyl]Pentanamide
11/03/2005US20050245741 Novel tricyclic spiropiperidines or spiropyrrolidines
11/03/2005US20050245736 Low molecular weight oversulfated polysaccharide
11/03/2005US20050245613 Use of gaba-b receptor positive modulators in gastro-intestinal disorders
11/03/2005US20050245602 Selective estrogen receptor modulators
11/03/2005US20050245597 Darifenacin solvate with toluene; mixing the free base with toluene to form the solvate, converting to the hydrate, addition salt formation with hydrogen bromide; high purity, extended shelf life; irritable bowel syndrome, incontinence and other gastrointestinal disorders
11/03/2005US20050245596 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
11/03/2005US20050245595 Positive modulators of nicotinic receptor agonists
11/03/2005US20050245592 2-Iminopyrrolidine derivatives
11/03/2005US20050245587 Treatment of dyskinesia
11/03/2005US20050245584 Peroxisome proliferator activated receptor agonists
11/03/2005US20050245581 3-(2-Cyanophenyl)-5-(2-methoxyphenyl)-1-phenyl-1,2-dihydropyridin-2-one; antagonists of AMPA and kainate receptors; neuroprotectants; neurodegenerative diseases; Alzheinmer's disease; antiepileptic agents; antispasmodic agents; anxiolytic agents; ddrug abuse; nervous sytem disorders; antihypoxic agents
11/03/2005US20050245576 Substituted pyrazoles
11/03/2005US20050245575 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
11/03/2005US20050245574 Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
11/03/2005US20050245571 Amine derivative
11/03/2005US20050245570 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
11/03/2005US20050245564 Methods and compositions related to IRM compounds and toll-like receptor pathways
11/03/2005US20050245562 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
11/03/2005US20050245561 Anti-tumour polycyclic carboxamides
11/03/2005US20050245552 N-substituted pyridinone and pyrimidinone derivatives for use as lp-pla2 inhibitors in the treatment of artherosclerosis
11/03/2005US20050245551 Amide derivatives
11/03/2005US20050245545 administering a xanthine derivative such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine
11/03/2005US20050245538 Dipeptidyl peptidase inhibitor; antidiabetic agents; obesity; viricides; anticancer agents; oral diseases; autoimmune disease
11/03/2005US20050245537 Use of compounds having ccr antagonism
11/03/2005US20050245527 Nitrogen containing heterocyclic compounds and medicines containing the same
11/03/2005US20050245525 Compounds useful for inhibiting CHK1
11/03/2005US20050245522 Novel compounds
11/03/2005US20050245514 Novel physiologically active substances
11/03/2005US20050245512 Method and composition for rejuvinating cells, tissues organs, hair and nails
11/03/2005US20050245511 Novel compounds that inhibit tryptase activity
1 ... 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 ... 1564